© EQS Newswire
09.09.2025
EUZ
LISTED
XETR
Berenberg startet Coverage mit „Kauf“-Empfehlung und Kursziel von 24 € – Kurspotenzial 47%
News Preview
Berlin, 9. September 2025. Die Eckert & Ziegler SE (ISIN DE0005659700), ein führender Anbieter von isotopentechnischen Komponenten für Nuklearmedizin und Messtechnik, wird künftig von der Hamburger Privatbank Joh. Berenberg, Gossler & Co. KG bewertet. In ihrer Initialstudie sprechen die Analysten eine „Kauf“-Empfehlung mit einem Kursziel vo......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.09.2025
EUZ
LISTED
XETR
Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
News Preview
Berlin, 9 September 2025. Eckert & Ziegler SE (ISIN DE0005659700), a leading supplier of isotope technology components for nuclear medicine and measurement technology, will be rated by the Hamburg-based private bank Joh. Berenberg, Gossler & Co. KG from now on. In their initial study, the analysts issue a “Buy” recommendation with a price t......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.09.2025
AGFB
LISTED
EURONEXT
Elevating Imaging, Empowering Flow - AGFA HealthCare at RSNA 2025
News Preview
Enabling clinicians to stay in flow-anytime, anywhere-with an intelligent, cloud-powered Enterprise Imaging Platform that is streaming-enabled, deeply integrated, and tailored to your workspace. CARLSTADT, NEW JERSEY / ACCESS Newswire / September 9, 2025 / At RSNA 2025, AGFA HealthCare will unveil its latest suite of imaging innovations designed to...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
09.09.2025
CLBX
LISTED
AIMX
Angle PLC Announces Interim Results
News Preview
ANGLE plc("ANGLE" or "the Company")Interim Results for the six months ended 30 June 2025COMMERCIALISATION PROGRESSED ACROSS MULTIPLE FRONTS DESPITE REVENUE PRESSURE FROM ADVERSE MARKET CONDITIONSLarge pharma contracts completed successfullyDNA Dual Analysis Illumina NGS assay for CTC-DNA and ctDNA developed GUILDFORD, SURREY / A...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
09.09.2025
CLBX
LISTED
AIMX
Angle PLC Announces Change of Adviser
News Preview
APPOINTMENT OF NOMINATED ADVISER AND SOLE BROKER GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has appointed Cavendish...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2025
DFTX
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grants
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 78,750 common...
Themefolio
Profiler
Peergroup
© ActuNews
08.09.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – September 8, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notification as follows:
Oxurion received a transparency notification on September 3, 2025, from...
Themefolio
Profiler
Peergroup
© ActuNews
08.09.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 8 september 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transpar...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
News Preview
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
NSIS B
LISTED
CPH
Novonesis and Novo Nordisk will explore new solutions to improve metabolic health
News Preview
Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
DBV
LISTED
EURONEXT
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
News Preview
Châtillon, France, September 5, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
FAGR
LISTED
EURONEXT
Disclosure of notification received from Mawer
News Preview
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 5 September 2025 – 5:40 PM CET...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
05.09.2025
ORX
LISTED
STO
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
News Preview
A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability th...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
ORX
LISTED
STO
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
News Preview
A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability th...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
BAVA
LISTED
CPH
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
News Preview
COPENHAGEN, Denmark, September 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 3,818,710 as a consequence of employees’ exercise of warrants....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
News Preview
CONSHOHOCKEN, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2025 to 17 new non-executive employees as equity inducem...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
AMRX
LISTED
NASDAQ
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
News Preview
BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen’s Risperdal Consta®. The product i...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
DFTX
LISTED
NASDAQ
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that JAMA has published full results from the Company’s positive Phase 2b study of MM120 (lysergide D-tartrate, LSD) in 198 adults with moder...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
News Preview
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
News Preview
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
LIVN
LISTED
NASDAQ
LivaNova Appoints Donald Zurbay as a New Director
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company’s Board of Directors, effective today. Zurbay will serve on the Audit and Compliance Committee for the Board.
“LivaNova is pleased to welcome Don to our Board of Directors,” said William Kozy, Chair of the Boa...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
TEM
LISTED
NASDAQ
Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform
News Preview
Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) today announced a notable expansion of their longstanding collaboration. Northwestern Medicine will be the first health system to integrate David, Tempus’ generative-AI clinical co-pilot, within its electronic health record (EHR) platform for its clinical care team. The expanded collaboration...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2025
ICLR
LISTED
NASDAQ
ICON Announces CEO Transition
News Preview
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON’s Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
POAI
LISTED
NASDAQ
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
News Preview
Collaboration builds upon positive results utilizing Predictive Oncology’s AI platform to identify new indications for existing drugs Collaboration builds upon positive results utilizing Predictive Oncology’s AI platform to identify new indications for existing drugs...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model
News Preview
STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate golexanolone provides sustained reversal of neuroinflammation in a Parkinson's disease model. The data, published in the scientific journal Frontiers in Im...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2025
NKTR
LISTED
NASDAQ
Nektar Therapeutics to Participate in Two Investor Conferences in September
News Preview
SAN FRANCISCO, Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York City and the Stifel Virtual Immunology and Inflammation Forum being held September 15-16,...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
TEM
LISTED
NASDAQ
Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference. The conference will take place September 8-10 in New York City. Eric Lefkofsky, Founder and CEO of Tempus, and Jim Rogers, Chief Financial Offi...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
DBV
LISTED
EURONEXT
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Châtillon, France, September 3, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
BIOA B
LISTED
STO
BioArctic's founders intend to divest minor part of their shareholding
News Preview
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, intend to divest a minor part of their respective shareholding.
This information is information that BioArctic AB (publ) is obliged to disclose pursua...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
BIOA B
LISTED
STO
BioArctic's founders intend to divest minor part of their shareholding
News Preview
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, intend to divest a minor part of their respective shareholding.
This information is information that BioArctic AB (publ) is obliged to disclose pursua...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
SN
LISTED
LSE
Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment. ...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
BIOA B
LISTED
STO
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
News Preview
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector, as a weekly star...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
BIOA B
LISTED
STO
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
News Preview
STOCKHOLM, Sept. 2, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector, as a weekly star...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
KPTI
LISTED
NASDAQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NEWTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 466 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of August 31, 2025 (the "Gr...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
HLN
LISTED
LSE
TUMS helps Second Harvest tackle hunger in Canada for the fourth year in a row
News Preview
TORONTO, Sept. 2, 2025 /CNW/ - Food waste is an avoidable problem, yet at least 10 million people continue to face food insecurity in Canada. In July 2025, StatsCan reported that the employment rate continued to drop, while also noting that there has been little net employment growth since the beginning of the year1. With numbers like this, it's...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
AFX
LISTED
XETR
ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones
News Preview
ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS from Sept. 12 - 15 in Copenhagen, Denmark:
EFFICIENT, CONFIDENT DECISION MAKING: introducing AI-powered CIRRUS® PathFinder™ clinical support tool now CE mark approved; presenting a fully integrated diagnostic and SLT therapeutic solution for managing...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ICLR
LISTED
NASDAQ
ICON plc to Participate at Upcoming Investor Conferences
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Barry Balfe, COO of ICON plc, will present at the Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 1:25 pm ET and Dr. Steve Cutler, CEO of ICON plc, will participate at the Deutsche Bank 20...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
OGI
LISTED
NASDAQ
Organigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada’s GDP in 2024
News Preview
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), Canada’s largest cannabis company by market share, today released "High Impact, Green Growth: The Economic Footprint of Canada's Cannabis Industry," a national report done in partnership with the Business Data Lab at the Canadian Chamber of Commerce. The report, which examined figures for 2024, unde...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
COLO B
LISTED
CPH
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4
News Preview
The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2025
COLO B
LISTED
CPH
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030
News Preview
...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
“Today’s approval of TIVDAK marks an important milestone for Za...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
OXUR
LISTED
EURONEXT
Oxurion bevestigt de vooruitgang van de onderhandelingen over haar strategie voor de diversificatie van de kasmiddelen; closing van de transactie wordt vóór 25 september 2025 verwacht
News Preview
Leuven, BELGIË – 1 september 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, kondigt aan dat de onderhandelingen met Atlas Special Opportunities over de financieringsovereenkomst constructief verlopen. De vennootschap verwacht de transactie vóó...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
OXUR
LISTED
EURONEXT
Oxurion confirme l'avancée des négociations relatives à sa stratégie de diversification de sa trésorerie ; un closing de l'opération est envisagé avant le 25 septembre 2025
News Preview
Louvain, Belgique, 1er septembre 2025, 18h00, Oxurion NV (Euronext Bruxelles : OXUR), entreprise biopharmaceutique basée à Louvain, annonce que les négociations avec Atlas Special Opportunities autour de la convention de financement avancent de manière constructive. La société envisage un closing de l'o...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
OXUR
LISTED
EURONEXT
Oxurion confirms progress in negotiations related to its treasury diversification strategy; closing of the transaction expected before September 25, 2025
News Preview
Leuven, BELGIUM – September 1, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that negotiations with Atlas Special Opportunities regarding the financing agreement are progressing constructively. The company expects to close the transaction before September...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – September 1, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on August 28, 2025, from A...
Themefolio
Profiler
Peergroup
© ActuNews
01.09.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 1 september 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transp...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
INTEG B
LISTED
STO
Integrum AB: Correction of Figures in Interim Report for the First Quarter 2025/26
News Preview
MÖLNDAL, Sweden, Sept. 1, 2025 /PRNewswire/ -- When publishing the interim report for the company, it was discovered that some of the total sums in the income statement show the wrong amounts. The sum of Net Sales and Work Performed by Own Use and Activated has mistakenly included Other operating income. Moreover, Other operating expenses was sum...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
RAY B
LISTED
STO
RaySearch launches RayIntelligence® v2025
News Preview
STOCKHOLM, Sept. 1, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) today announced the release of RayIntelligence®* v2025, a major update to its oncology analytics system designed to transform clinical data into actionable insights. With new tools for building customized dashboards and deeper integration across RaySearch's product portfoli...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
SECT_B
LISTED
STO
University medical center in Germany expands use of Sectra's solution with AI service--accelerates adoption of AI for enhanced efficiency and patient care
News Preview
LINKÖPING, Sweden, Sept. 1, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that Universitätsmedizin Göttingen (UMG Göttingen) in Germany will expand its enterprise imaging solution to include Sectra's AI service, Sectra Amplifier Service. The AI service, operated within Microsoft Azu...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
INTEG B
LISTED
STO
Integrum AB: Stronger positioning paves the way for continued growth
News Preview
MÖLNDAL, Sweden, Sept. 1, 2025 /PRNewswire/ --
First quarter 2025/26 (May - July)
Net sales amounted to SEK 23.8 (18.5) million.Operating loss totalled SEK 12.4 (12.0) million.Profit/loss after tax amounted to SEK -10.0 (-9.4) million.Earnings per share amounted to SEK -0.47 (-0.49).Cash flow totalled SEK -12.4 (29.3) million.Significant events...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2025
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva SE | Rating: Buy
News Preview
Original-Research: Valneva SE - von First Berlin Equity Research GmbH
29.08.2025 / 16:48 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Au......
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
ERF
LISTED
EURONEXT
Eurofins Viracor BioPharma Announces Relocation to New State-of-the-Art Facility
News Preview
Eurofins Viracor BioPharma Services, a recognized leader in analytical testing and clinical trial services, announces the infrastructure enhancement of its headquarters and laboratory operations to a new, custom-built 96,000 sq. ft. facility in Lenexa, Kansas, scheduled for completion in September 2025. This strategic move, although only a few mil...
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2025
SOBI
LISTED
STO
New number of shares and votes in Sobi
News Preview
STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049 are common shares and 1,412,788 are C-shares. The total number of votes is 356,141,327,8. The increase in the number of shares and votes results from issues of...
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2025
SOBI
LISTED
STO
New number of shares and votes in Sobi
News Preview
STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049 are common shares and 1,412,788 are C-shares. The total number of votes is 356,141,327,8. The increase in the number of shares and votes results from issues of...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2025
GXI
LISTED
XETR
Wolf Lehmann übernimmt zum 1. September 2025 CFO-Position bei Gerresheimer
News Preview
Wolf Lehmann übernimmt zum 1. September 2025 CFO-Position bei GerresheimerInternational erfahrener Finanzexperte tritt Nachfolge von Dr. Bernd Metzner an
Düsseldorf, 29. August 2025. Der Aufsichtsrat der Gerresheimer AG hat Wolf Lehmann zum Chief Financial Officer (CFO) bestellt. Er folgt zum 1. September 2025 auf Dr. Bernd Metzner, der Gerreshe......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2025
GXI
LISTED
XETR
Wolf Lehmann to take over CFO position at Gerresheimer on September 1, 2025
News Preview
Wolf Lehmann to take over CFO position at Gerresheimer on September 1, 2025
Internationally experienced finance expert to succeed Dr. Bernd Metzner
Duesseldorf, August 29, 2025. The Supervisory Board of Gerresheimer AG has appointed Wolf Lehmann as Chief Financial Officer (CFO). He will succeed Dr. Bernd Metzner on September 1, 2025, who is leavi......
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2025
UCB
LISTED
EURONEXT
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
News Preview
26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsiesData include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndr...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
KDEV
LISTED
STO
Interim Report - January-June 2025
News Preview
STOCKHOLM – 29 August 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-June 2025. The full report is available on the Company's website....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
News Preview
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
